AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8818742 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 52
Study 8818742 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 52
Study 1899364 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg rt-PA with heparin and aspirin
Number of subjects: 908
Study 1899364 — intervention group
Group type: COMPARATOR
Intervention: 100 mg rt-PA with heparin and aspirin
Number of subjects: 908
Study 1899364 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with any history of neurological disease
Number of subjects: 908
Study 1899364 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with intracerebral hemorrhage
Number of subjects: 908
Study 7052115 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) vaginal tablet (3 mg)
Number of subjects: 100
Study 7052115 — intervention group
Group type: COMPARATOR
Intervention: Amniotomy and intravenous oxytocin
Number of subjects: 100
Study 30477911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus masking therapy and sound treatment
Number of subjects: 100
Study 30477911 — intervention group
Group type: COMPARATOR
Intervention: Masking therapy and sound treatment
Number of subjects: 100
Study 27730478 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation Training (AOT-G)
Number of subjects: 42
Study 27730478 — intervention group
Group type: COMPARATOR
Intervention: Control Group (C-G)
Number of subjects: 42
Study 27730478 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 42
Study 25833772 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diet with 3-4 dairy product servings (2092 kJ/d reduction) over 12 weeks
Number of subjects: 67
Study 24655622 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25-50mg/day
Number of subjects: 628
Study 24655622 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20-40mg/day
Number of subjects: 628
Study 22467985 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine monitoring system (PAP adherence with telemedicine)
Number of subjects: 75
Study 22467985 — intervention group
Group type: COMPARATOR
Intervention: Standard care (PAP adherence without telemedicine)
Number of subjects: 75
Study 22467985 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine monitoring system (PAP adherence on days used)
Number of subjects: 75
Study 22467985 — intervention group
Group type: COMPARATOR
Intervention: Standard care (PAP adherence on days used)
Number of subjects: 75
Study 22467985 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine monitoring system (technician time)
Number of subjects: 75
Study 19534021 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/d for 6 months
Number of subjects: 0
Study 19534021 — intervention group
Group type: COMPARATOR
Intervention: Pre-existing treatments without spironolactone
Number of subjects: 0
Study 17519271 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral leflunomide (LEF) 30 mg/day
Number of subjects: 54
Study 17519271 — intervention group
Group type: COMPARATOR
Intervention: Oral methotrexate (MTX) starting with 7.5 mg/week reaching 20 mg/week after 8 weeks
Number of subjects: 54
Study 15221659 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic amoxicillin/metronidazole plus chlorhexidine
Number of subjects: 35
Study 15221659 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement alone
Number of subjects: 35
Study 11293554 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel (0.1%)
Number of subjects: 36
Study 11293554 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene cream (0.1%)
Number of subjects: 36
Study 11293554 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (4%)/tretinoin (0.025%) solution
Number of subjects: 36
Study 11293554 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (4%)/tretinoin (0.025%) gel
Number of subjects: 36
Study 11293554 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (2%)/isotretinoin (0.05%) gel
Number of subjects: 36
Study 11293554 — intervention group
Group type: COMPARATOR
Intervention: White petrolatum (negative control)
Number of subjects: 36
Study 9711101 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test
Number of subjects: 0
Study 9711101 — intervention group
Group type: COMPARATOR
Intervention: Positive exercise test result
Number of subjects: 0
Study 7697479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ragweed challenge (doses 10, 100, and 1000 PNU)
Number of subjects: 18
Study 7697479 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 18
Study 2745339 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 ppm O3
Number of subjects: 15
Study 2745339 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 ppm O3
Number of subjects: 15
Study 2745339 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 15
Study 821168 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 15
Study 821168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Cromoglycate
Number of subjects: 15
Study 821168 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline Theophyllinate
Number of subjects: 15
Study 821168 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine Methonitrate
Number of subjects: 15
Study 821168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31904863 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 209
Study 29308962 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio® taping
Number of subjects: 39
Study 26360147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical positive sagittal malalignment (CPSM)
Number of subjects: 182
Study 26360147 — intervention group
Group type: COMPARATOR
Intervention: No baseline cervical deformity (NONE)
Number of subjects: 182
Study 26360147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical kyphosis (CK)
Number of subjects: 182
Study 24252717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin administration
Number of subjects: 35
Study 24252717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 22077070 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 25(OH)D levels
Number of subjects: 973
Study 22077070 — intervention group
Group type: COMPARATOR
Intervention: Daily azithromycin
Number of subjects: 973
Study 20033726 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable sutures (AS) with tacks
Number of subjects: 199
Study 20033726 — intervention group
Group type: EXPERIMENTAL
Intervention: Double crown (DC) with tacks
Number of subjects: 199
Study 20033726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonabsorbable sutures (NS) with tacks
Number of subjects: 199
Study 20033726 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL survey
Number of subjects: 199
Study 17188409 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 2g combined with clavulanic acid, orally daily for 5 days postoperatively
Number of subjects: 150
Study 17188409 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 2g combined with clavulanic acid, starting 5 days before the operation
Number of subjects: 150
Study 17188409 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 150
Study 15654549 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 mcg subcutaneously three times weekly (tiw)
Number of subjects: 677
Study 15654549 — intervention group
Group type: COMPARATOR
Intervention: 30 mcg intramuscularly once weekly (qw)
Number of subjects: 677
Study 11238511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) (400-600 IU/day) and calcium (500 mg/day)
Number of subjects: 7564
Study 9550248 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management plus marital intervention for 11 months
Number of subjects: 0
Study 9550248 — intervention group
Group type: COMPARATOR
Intervention: Medication management
Number of subjects: 0
Study 9550248 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management plus marital intervention
Number of subjects: 0
Study 7942680 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg each morning
Number of subjects: 27
Study 3227297 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg oral propranolol twice daily for 7 days
Number of subjects: 20
Study 3227297 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 7 days
Number of subjects: 20
Study 2232492 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham hemodialysis with regenerated cellulose membrane (Group CU)
Number of subjects: 24
Study 2232492 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham hemodialysis with indomethacin administration (Group CU-IND)
Number of subjects: 24
Study 2232492 — intervention group
Group type: COMPARATOR
Intervention: Sham hemodialysis with polyacrylonitrile membrane (Group AN)
Number of subjects: 24
Study 5350103 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Number of subjects: 90
Study 5350103 — intervention group
Group type: COMPARATOR
Intervention: 1-hyoscyamine
Number of subjects: 90
Study 5350103 — intervention group
Group type: COMPARATOR
Intervention: Inert tablets (placebo)
Number of subjects: 90
Study 31874890 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based physical activity intervention with tailored advice only
Number of subjects: 300
Study 31874890 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based physical activity intervention with tailored advice and Fitbit
Number of subjects: 300
Study 31874890 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 300
Study 28672319 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation combined with a standardized exercise program
Number of subjects: 681
Study 28672319 — intervention group
Group type: COMPARATOR
Intervention: Standardized exercise program alone
Number of subjects: 681
Study 25781025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Zoledronic Acid (ZA), 2 doses, 3 weeks apart
Number of subjects: 30
Study 25781025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23674934 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 134
Study 23674934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 21108032 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive e-coach support
Number of subjects: 104
Study 21108032 — intervention group
Group type: COMPARATOR
Intervention: Nondirective e-coach support
Number of subjects: 104
Study 21108032 — intervention group
Group type: COMPARATOR
Intervention: Minimal support
Number of subjects: 104
Study 19242921 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention for breast cancer patients over 12 weeks
Number of subjects: 0
Study 19242921 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention for breast cancer patients
Number of subjects: 0
Study 17270336 — intervention group
Group type: COMPARATOR
Intervention: Semi-automatic defibrillation (AED)
Number of subjects: 32
Study 17270336 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual defibrillation (MED)
Number of subjects: 32
Study 15197018 — intervention group
Group type: EXPERIMENTAL
Intervention: Low- to moderate-intensity aerobic exercise
Number of subjects: 140
Study 15197018 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activity)
Number of subjects: 140
Study 11485158 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% GLA (borage oil)
Number of subjects: 66
Study 11485158 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% GLA, 0.3% DHA, 0.06% EPA (borage oil + fish oil low)
Number of subjects: 66
Study 11485158 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% GLA, 0.3% DHA, 0.2% EPA (borage oil + fish oil high)
Number of subjects: 66
Study 11485158 — intervention group
Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 66
Study 9858950 — intervention group
Group type: EXPERIMENTAL
Intervention: Retarded morphine (mean dosage: 49.2 +/- 28.4 mg/d)
Number of subjects: 20
Study 9858950 — intervention group
Group type: COMPARATOR
Intervention: Control (no further therapy)
Number of subjects: 20
Study 8116539 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g native amylomaize (Hylon‐VII) three times a day for 7 days, containing 28 g type II resistant starch
Number of subjects: 19
Study 8116539 — intervention group
Group type: COMPARATOR
Intervention: Dextrins as a placebo
Number of subjects: 19
Study 3291491 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 ml PG E2 endocervical application
Number of subjects: 160
Study 3291491 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg intravaginal PG E2
Number of subjects: 160
Study 3291491 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin sensitivity test
Number of subjects: 160
Study 3291491 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 vaginal tablets
Number of subjects: 160
Study 31189698 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative RUTF
Number of subjects: 1270
Study 31189698 — intervention group
Group type: COMPARATOR
Intervention: Standard RUTF
Number of subjects: 1270
Study 25300225 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-only dietary energy density (ED)
Number of subjects: 172
Study 23070146 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg twice a day for 3 days, followed by nilotinib 400 mg on Day 4 (famotidine given 2 h after nilotinib)
Number of subjects: 52
Study 23070146 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid suspension 20 mL given 2 h before nilotinib 400 mg
Number of subjects: 52
Study 23070146 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid suspension 20 mL given 2 h after nilotinib 400 mg
Number of subjects: 52
Study 23070146 — intervention group
Group type: COMPARATOR
Intervention: Nilotinib 400 mg alone
Number of subjects: 52
Study 20699330 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered chemotherapy
Number of subjects: 99
Study 19097705 — intervention group
Group type: EXPERIMENTAL
Intervention: TOT-AL online measure of past week alcohol consumption
Number of subjects: 0
Study 16760903 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolyzed-reduced water (ERW) treatment for 6 months
Number of subjects: 43
Study 16760903 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C treatment
Number of subjects: 43
Study 16760903 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E-coated dialyzer treatment
Number of subjects: 43
Study 16760903 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 43
Study 15205236 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin tissue adhesive (Tisseel Duo Quick)
Number of subjects: 43
Study 15205236 — intervention group
Group type: COMPARATOR
Intervention: Absorbable sutures (7‐0 Vicryl Rapid)
Number of subjects: 43
Study 11320367 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate left ventricular hypertrophy (iLVH)
Number of subjects: 659
Study 11320367 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric iLVH
Number of subjects: 659
Study 11320367 — intervention group
Group type: COMPARATOR
Intervention: Concentric aLVH
Number of subjects: 659
Study 11320367 — intervention group
Group type: COMPARATOR
Intervention: Eccentric aLVH
Number of subjects: 659
Study 11320367 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (iLVH and aLVH)
Number of subjects: 659
Study 9227725 — intervention group
Group type: EXPERIMENTAL
Intervention: Short wave diathermy for 25 minutes each day (n = 11)
Number of subjects: 22
Study 9227725 — intervention group
Group type: COMPARATOR
Intervention: Observation with bed rest (n = 11)
Number of subjects: 22
Study 9227725 — intervention group
Group type: EXPERIMENTAL
Intervention: Short wave diathermy
Number of subjects: 22
Study 9227725 — intervention group
Group type: COMPARATOR
Intervention: Observation with bed rest
Number of subjects: 22
Study 8260445 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic withdrawal (haloperidol)
Number of subjects: 15
Study 2888942 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril alone
Number of subjects: 14
Study 2888942 — intervention group
Group type: COMPARATOR
Intervention: Frusemide plus amiloride
Number of subjects: 14
Study 29144182 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-Lyte 148 (PL)
Number of subjects: 50
Study 29144182 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's solution (HS)
Number of subjects: 50
Study 29144182 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-Lyte 148 (PL) and Hartmann's solution (HS)
Number of subjects: 50
Study 26850941 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Number of subjects: 8160
Study 26850941 — intervention group
Group type: COMPARATOR
Intervention: Pap test reminders (Control)
Number of subjects: 8160
Study 23868538 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume Guarantee (VG) ventilation (Vt=5 mL/kg, PEEP=5 cmH2O)
Number of subjects: 25
Study 23868538 — intervention group
Group type: COMPARATOR
Intervention: High Frequency Oscillatory Ventilation (HFOV)
Number of subjects: 25
Study 22267455 — intervention group
Group type: EXPERIMENTAL
Intervention: Biaxial microincision (B-MICS)
Number of subjects: 42
Study 20346539 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 212
Study 20346539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 18551076 — intervention group
Group type: EXPERIMENTAL
Intervention: BRANDS allocation scheme
Number of subjects: 40
Study 18551076 — intervention group
Group type: COMPARATOR
Intervention: UK National Allocation Scheme (NAS)
Number of subjects: 40
Study 15946978 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 907
Study 15946978 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 907
Study 12002664 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate ophthalmic gel-forming solution QD
Number of subjects: 133
Study 12002664 — intervention group
Group type: COMPARATOR
Intervention: 0.5% levobunolol hydrochloride BID
Number of subjects: 133
Study 9950291 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncated area (AUCt) for amiodarone
Number of subjects: 24
Study 9950291 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncated area (AUCt) for danazol
Number of subjects: 24
Study 9950291 — intervention group
Group type: COMPARATOR
Intervention: Area to the last quantifiable time point (AUC(0-T)) for amiodarone
Number of subjects: 24
Study 9950291 — intervention group
Group type: COMPARATOR
Intervention: Area to the last quantifiable time point (AUC(0-T)) for danazol
Number of subjects: 24
Study 7791837 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive transfusion regimen (designed to decrease hemoglobin S level to less than 30 percent)
Number of subjects: 604
Study 7791837 — intervention group
Group type: COMPARATOR
Intervention: Conservative transfusion regimen (designed to increase hemoglobin level to 10 g per deciliter)
Number of subjects: 604
Study 7791837 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive transfusion regimen
Number of subjects: 604
Study 7791837 — intervention group
Group type: COMPARATOR
Intervention: Conservative transfusion regimen
Number of subjects: 604
Study 7791837 — intervention group
Group type: EXPERIMENTAL
Intervention: Both aggressive and conservative transfusion regimens
Number of subjects: 604
Study 2189906 — intervention group
Group type: EXPERIMENTAL
Intervention: R 68 151 2% ointment
Number of subjects: 88
Study 2189906 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 88
Study 74662 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-globulin concentrate as adjunctive therapy
Number of subjects: 195
Study 74662 — intervention group
Group type: COMPARATOR
Intervention: standard immunosuppressive regimen (control group)
Number of subjects: 195
Study 74662 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-globulin concentrate
Number of subjects: 195
Study 31313270 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 94-9027 (extended half-life factor VIII replacement therapy) infused once every 7 days, once every 5 days, or twice weekly
Number of subjects: 16
Study 31313270 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 94-9027
Number of subjects: 16
Study 28656968 — intervention group
Group type: EXPERIMENTAL
Intervention: Home jejunostomy feeding (n=18)
Number of subjects: 41
Study 28656968 — intervention group
Group type: COMPARATOR
Intervention: Usual care without feeding (n=23)
Number of subjects: 41
Study 28656968 — intervention group
Group type: COMPARATOR
Intervention: Rescue feeding (n=6)
Number of subjects: 41
Study 27465608 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion in thermoneutral water (ITW) for 45-60 min, 4 times a week for 4 weeks
Number of subjects: 59
Study 27465608 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion in thermoneutral water (ITW) for 45-60 min, 4 times a week for 4 weeks, then reduced to 1 bath a week for 20 weeks (Bath1)
Number of subjects: 59
Study 27465608 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion in thermoneutral water (ITW) for 45-60 min, 4 times a week for 4 weeks (Bath2)
Number of subjects: 59
Study 27465608 — intervention group
Group type: COMPARATOR
Intervention: Control group instructed to relax for 45-60 min, 4 times a week for 24 weeks using a relaxation CD
Number of subjects: 59
Study 24774590 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional management of heart failure and an individualized nutritional intervention (optimization of diet, specific recommendations, and nutritional supplements if necessary)
Number of subjects: 182
Study 24774590 — intervention group
Group type: COMPARATOR
Intervention: Conventional management of heart failure
Number of subjects: 182
Study 22395092 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 319
Study 22395092 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 319
Study 22395092 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 319
Study 20882526 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with ciprofloxacin, orally, and vancomycin, intravenously
Number of subjects: 157
Study 20882526 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 157